

# $\gamma$ -Valerolactone (GVL): A Bio-Based Dipolar Aprotic Solvent for More Sustainable Synthesis

Saikat Sinha<sup>1</sup>, R&D Lead, Customer Solution R&D

Markus Obkircher<sup>1</sup>, Head of Customer Solutions R&D

Rhushikesh Deokar<sup>1</sup>, Senior Scientist R&D

Muralikrishna Yaragani<sup>1</sup>, Senior Scientist R&D

Thrilokraj R<sup>1</sup>, Scientist R&D

John Cooper<sup>2</sup>, Senior Global Product Manager, Analytical Essentials

<sup>1</sup>Sigma-Aldrich Chemical Pvt. Ltd. (Bangalore, India)

<sup>2</sup>MilliporeSigma (Milwaukee, United States)

## Abstract

The advancement of more sustainable practices in organic synthesis increasingly hinges on the adoption of bio-based solvents. Traditional dipolar aprotic solvents such as *N,N*-dimethylformamide (DMF), *N*-methyl-2-pyrrolidone (NMP), and *N,N*-dimethylacetamide (DMAc) are widely used but present serious environmental and safety concerns due to their toxicity, poor biodegradability, and regulatory restrictions.  $\gamma$ -Valerolactone (GVL, **933856**), a bio-based solvent derived from lignocellulosic biomass, offers synthetic chemists a compelling alternative solvent with favorable properties including high polarity, thermal stability, low toxicity, and excellent biodegradability. This application note demonstrates the potential of GVL to replace conventional solvents in key organic transformations - including Pd-cross coupling, nucleophilic aliphatic and aromatic substitution, amidation - while maintaining comparable or improved reaction efficiency. By highlighting GVL's broad applicability and environmental advantages, this work positions it as a practical, more sustainable alternative for modern organic synthesis.

## Introduction

Conventional solvents such as *N,N*-dimethylformamide (DMF), *N*-methyl-2-pyrrolidone (NMP), *N,N*-Dimethylacetamide (DMAc), 1,4-dioxane and tetrahydrofuran (THF) offer strong solvating capabilities but are associated with toxicity, regulatory pressure, and poor biodegradability<sup>1a-i</sup>. The chemical industry is therefore actively seeking high-performance, bio-based alternatives to reduce their environmental footprint.  $\gamma$ -Valerolactone (GVL, **Figure 1**) is one such candidate,

derived from lignocellulosic biomass *via* the catalytic hydrogenation and cyclization of levulinic acid.<sup>1k-l</sup>

As a biomass-derived, biodegradable (OECD Test Guideline 301B) and low-toxicity solvent, GVL conforms to multiple principles of "Green Chemistry"<sup>1j</sup>, notably Principle 5 (safer solvents and auxiliaries), Principle 7 (use of renewable feedstocks), Principle 10 (design for degradation) and Principle 3 (less hazardous chemical syntheses), supporting its adoption as a more sustainable alternative in synthetic and formulation processes. Its properties - namely high polarity, thermal stability, low vapor pressure, and miscibility with both aqueous and organic media (**Table 1 & 2**) - make it a versatile replacement for hazardous dipolar aprotic solvents in many synthetic applications.

GVL has been highlighted in solvent selection frameworks such as the GSK solvent sustainability guide<sup>1c</sup> and the CHEM21 solvent selection guide<sup>1d</sup>, which systematically rank solvents based on safety, health and environmental metrics. Both resources recommend GVL due to its low flammability, low toxicity and excellent environmental profile. As such, GVL is being increasingly adopted in key transformations including Pd-catalyzed cross-coupling, nucleophilic aromatic substitution, and amide bond formation, where it has shown yields comparable to or better than conventional solvents.<sup>2</sup>

This application note focuses on evaluating GVL's performance in key reaction classes that are commonly dependent on dipolar aprotic solvents: nucleophilic substitution, amidation, and palladium-catalyzed cross-coupling. These reactions were selected because they

are foundational to pharmaceutical and fine chemical synthesis and typically require solvents with strong polar characteristics. By demonstrating GVL's effectiveness in these transformations, we aim to provide practical guidance for its adoption in greener synthetic workflows.




Figure 1.  $\gamma$ -Valerolactone (GVL).

Table 1. Properties of  $\gamma$ -Valerolactone (GVL)

<b>CAS Number:</b>	<b>108-29-2</b>
<b>Molar Mass:</b>	100.12 g/mol
<b>Chemical Formula:</b>	C <sub>5</sub> H <sub>8</sub> O <sub>2</sub>
<b>Boiling Point:</b>	207 °C
<b>Melting Point:</b>	-31 °C
<b>Flash Point:</b>	81 °C (closed cup)
<b>Density at 20 °C:</b>	1.0546 g/mL
<b>Viscosity:</b>	2.18 mPa·s (cP) at 298.15 K
<b>Refractive Index (n<sub>d</sub>):</b>	1.4333 at 298.15 K
<b>Vapor Pressure:</b>	30–44 Pa at 298.15 K
<b>Surface Tension:</b>	~30 dyne/cm at 298.15 K
<b>Dielectric Constant:</b>	~ 36.14

Table 2. Comparison of solubility of  $\gamma$ -Valerolactone (GVL) with water and common organic solvents

Water miscibility	Polar protic and aprotic solvents	Non-polar hydrophobic solvents
GVL is highly soluble in water, with solubility exceeding 100 mg/mL	Ethanol, Methanol: Miscible	Toluene: Limited solubility
	Acetone, DMSO: Miscible	Hexane: Poor solubility
	Acetonitrile: Acts as a non-solvent in some ionic liquid systems	Diethyl ether: Moderate solubility

## GVL as a Greener Alternative to Hazardous Organic Solvents

GVL offers a compelling combination of high performance and sustainability characteristics, making it an appealing more sustainable alternative to traditional dipolar aprotic solvents. Derived from renewable resources, it addresses increasing regulatory and safety pressures by delivering comparable reactivity without the associated toxicity or persistence.<sup>3</sup> Its compatibility with diverse reaction conditions - ranging from cross-couplings to nucleophilic substitutions - further supports its role in greener synthetic workflows. As such, GVL stands out as a practical and forward-looking solution for modern organic synthesis. Here are few application examples for GVL to replace hazardous solvents in industry.

### Pharmaceutical and Polymer Manufacturing

GVL's solvating power enables it to substitute effectively for hazardous solvents in pharmaceutical synthesis, polymer processing, and crystallization steps, offering

comparable performance with enhanced safety. Fodor<sup>4a</sup> *et al.* (2020) demonstrated GVL's successful application in homogeneous, phosphine-free Pd-catalyzed Heck coupling reactions. Their study revealed high functional group tolerance, moisture stability and catalytic performance comparable to DMF. Detailed kinetic and computational analyses confirmed that GVL supports efficient catalysis under mild conditions without altering the reaction mechanism. Complementing this, Kerke<sup>4b</sup> *et al.* (2021) provided a comprehensive environmental and physicochemical profile of GVL, confirming its ready biodegradability and low toxicity across various aquatic species. Moreover, modeling approaches such as Hansen solubility parameters and COSMO-RS indicated that GVL closely resembles solvents like DMF and NMP, underscoring its potential as a safer substitute in pharmaceutical, polymer, cleaning, and cosmetic applications.

Further expanding on GVL's catalytic utility, Strappaveccia<sup>4c</sup> *et al.* applied it in Pd-catalyzed Heck-Mizoroki coupling reactions for both small-molecule synthesis and the production of conjugated polymers such as poly(phenylenevinylene) (PPV) derivatives. GVL demonstrated comparable polarity, high thermal stability, and low toxicity while significantly reducing palladium leaching - achieving residual metal contents as low as 6 ppm compared to over 800 ppm in NMP. This reduction minimizes downstream purification requirements and enhances the overall sustainability of the process. The resulting polymeric materials exhibited excellent optoelectronic performance in organic photovoltaic and transistor devices, validating GVL's suitability for greener and scalable synthesis of semiconducting materials.

Together, these studies establish GVL as a more sustainable, low-toxicity, and high-performance solvent with broad applicability in greener chemistry, particularly in pharmaceutical manufacturing, catalysis, and advanced materials processing.

### Printed Electronics

$\gamma$ -Valerolactone (GVL) has also emerged as a transformative greener solvent in the field of printed electronics, particularly in perovskite solar cell (PSC) fabrication. Derived from renewable biomass, GVL offers a low-toxic, biodegradable alternative to conventional solvents like DMF and  $\gamma$ -butyrolactone (GBL). While GBL is not highly toxic, its psychoactive properties and associated legal restrictions pose significant barriers to widespread adoption. The 2021 study by Worsley<sup>5a</sup> *et al.* demonstrated that GVL can effectively replace GBL in mesoscopic carbon-based PSCs, achieving comparable power conversion efficiencies (PCEs) and enhanced device stability under prolonged illumination and thermal stress. Complementing this, Miao<sup>5b</sup> *et al.* (2023) showcased GVL's exceptional ink stability—maintaining performance after one year of storage—and its compatibility with scalable processing, enabling the fabrication of high-efficiency PSCs (PCE >25%) and certified mini-modules (>20%) without the need for toxic antisolvents. Together, these studies establish GVL not only acts as a safer and more sustainable solvent but also as a performance-enhancing material for next-generation photovoltaic technologies.

## Co-solvent with Ionic Liquids

GVL emerges as a greener, more sustainable, and highly effective solvent for polymer dissolution, offering a low-toxic alternative to conventional harsh chemicals. In combination with imidazolium-based ionic liquids like [C<sub>8</sub>MIm][Cl], GVL exhibits remarkable synergistic effects, significantly enhancing polymer solubility. This innovative solvent system not only enables efficient processing of robust polyaramids but also aligns with principles of Green Chemistry, paving the way for more sustainable materials science and extraction technologies.<sup>6</sup>

## Results and Discussion

This application note presents a series of representative organic reactions to demonstrate the versatility and effectiveness of GVL as a renewable dipolar aprotic solvent. These examples highlight its ability to replace conventional polar aprotic solvents such as DMF, NMP and DMAc in common chemical transformations without compromising efficiency or selectivity. A summary of the reaction conditions and yields is provided in **Table 3**.

The selected reactions include amide bond formation, nucleophilic substitution, and palladium-catalyzed C–C coupling, all of which are relevant to pharmaceutical and fine chemical synthesis. These reactions are commonly carried out in DMF, NMP and DMAc due to their strong solubilizing ability and polarity. GVL's comparable solvating power, high thermal and chemical stability, and low toxicity make it a promising alternative across these reaction classes.

Key examples include acid–amine coupling using HATU and DIPEA in GVL, enabling high-yielding amide formation under mild conditions. GVL demonstrated good performance as a reaction medium in the synthesis of peptidomimetics, amino acid derivatives, and functionalized small molecules, achieving yields in the range of 75–85% in multiple cases. In addition, GVL was successfully used in a Pd(II)-catalyzed cross-coupling reaction involving *tert*-butyl (4-bromobenzyl)carbamate and 4-methylthiazole, showing excellent compatibility with organometallic catalysis and replacing NMP effectively.

GVL also supported more challenging transformations like the synthesis of substituted isoindolinones and diazaspirones, both of which benefit from the solvent's ability to dissolve polar intermediates and facilitate clean product isolation *via* precipitation or extraction. In reactions requiring column purification, GVL left minimal residue and showed easy removability under reduced pressure.

These diverse examples reinforce GVL's practical utility as a viable substitute for traditional dipolar aprotic solvents in both batch and potential continuous-flow applications. The reaction protocols employed standard laboratory conditions and illustrated GVL's compatibility with scalable, more sustainable synthetic chemistry. Details of all experimental conditions and spectral data are provided in the **Appendix**.


### 1. Substitution Reactions

Substitution reactions are widely used in synthetic chemistry and represent a practical context to evaluate

greener solvent alternatives. This application note investigates the performance of GVL, a more sustainable solvent, in facilitating representative substitution reactions - including halogenation and O-/N-alkylation - commonly employed in synthetic laboratories. Our experimental results demonstrate that GVL can successfully replace conventional dipolar aprotic solvents such as THF, 1,4-dioxane, NMP, DMF, and DMAc with no loss in yield or efficiency. These findings support GVL's utility as a viable and more sustainable solvent platform for both academic and industrial synthesis.

#### 1.1. Nucleophilic Aromatic Substitution (S<sub>N</sub>Ar) Reaction

Nucleophilic Aromatic Substitution (S<sub>N</sub>Ar) is a key strategy for functionalizing electron-deficient aromatic systems, proceeding *via* a Meisenheimer complex. Solvent choice critically influences reaction efficiency, with polar aprotic solvents like DMF, NMP, DMAc, THF and 1,4-dioxane commonly used to stabilize intermediates and enhance nucleophilicity. Recent studies highlight solvent-dependent mechanistic variations, including shifts toward single-electron transfer (SET) pathways. In this context, GVL emerges as a greener alternative, effectively supporting S<sub>N</sub>Ar reactivity.<sup>7a,b</sup> In the example below (**Figure 2**), 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindolin-1,3-dione **1** was reacted with 1-Boc-piperazine **343536** in GVL under heating conditions to afford *tert*-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate **2** in 87% yield whereas the same reaction yields are 82% and 79% in DMF and NMP respectively. This transformation demonstrates GVL's capacity to support S<sub>N</sub>Ar reactivity while offering a greener alternative to conventional solvents such as DMF or NMP.



**Figure 2.** Synthesis of *tert*-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)piperazine-1-carboxylate **2** through nucleophilic aromatic substitution (S<sub>N</sub>Ar) reaction of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindolin-1,3-dione **1** and 1-Boc-piperazine **343536** in GVL **933856**.

#### 1.2. N-Alkylation


Substitution reactions involving alkyl halides and other leaving groups are commonly performed in toxic dipolar aprotic solvents such as DMF, NMP and DMSO, often in the presence of phase-transfer catalysts. In this context, GVL has been demonstrated as a viable greener alternative, supporting efficient nucleophilic substitution without the need for hazardous media. We report two representative examples conducted in GVL, both yielding over 80%.

In the first case, 7-benzyl 2-(*tert*-butyl) 2,7-diazaspiro[3.5]nonane-2,7-dicarboxylate **4** was synthesized *via* the substitution of *tert*-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate **3** with 1-benzyl-2-bromoacetate **245631** in GVL in 98% yield compare to 76% yield in DMF.


In the second example, 3-(5-nitro-1-oxo-2,3-dihydro-1*H*-isoindol-2-yl)piperidine-2,6-dione **7** was obtained

in 83% yield *via* the reaction of 2-(bromomethyl)-4-nitrobenzoate **5** with 3-aminoglutarimide hydrochloride **6**, also in GVL. A comparable yield of 82% was obtained when the reaction was carried out in DMF.

Notably, both diazaspino scaffolds and thalidomide<sup>8</sup> derivatives are privileged structures in medicinal chemistry, frequently explored for their therapeutic potential in Central Nervous System (CNS) disorders, oncology, and immunomodulation. The successful execution of such transformations in GVL underscores its promise as a more sustainable solvent for drug discovery and development workflows.



**Figure 3.** Synthesis of *tert*-butyl 7-(2-(benzyloxy)-2-oxoethyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate **4** via substitution reaction between *tert*-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate **3** and 1-benzyl-2-bromoacetate **245631** in GVL **933856**.



**Figure 4.** Synthesis of 3-(5-nitro-1-oxoisindolin-2-yl) piperidine-2,6-dione **7** through Substitution Reaction of 2-(bromomethyl)-4-nitrobenzoate **5** and 3-aminoglutarimide hydrochloride **6** in GVL **933856**.

## 2. Amidation Reaction


Amidation reactions are fundamental to pharmaceutical and peptide synthesis, enabling the formation of amide bonds that are ubiquitous in drug molecules and bioactive compounds. Traditionally, these reactions are conducted in polar aprotic solvents such as DMF, NMP and DCM, which provide excellent solvation for carboxylic acids, amines, and coupling reagents. However, these solvents are associated with significant health and environmental concerns: they are reprotoxic, poorly biodegradable and increasingly subject to regulatory restrictions.

In response to these challenges, recent studies<sup>9</sup> have explored the use of bio-based alternatives, such as GVL, which has shown promising compatibility with commonly used coupling agents. Although direct investigations of GVL with specific agents like HATU, EDC and DIC remain limited, emerging evidence supports its potential in greener amidation protocols. For example, a study<sup>10</sup> evaluating the stability of coupling reagents in various solvents found that COMU<sup>®</sup>, a widely used coupling agent, retained 84% of its integrity in GVL after 48 hours, in contrast to its complete degradation in DMF over the same period.

Moreover, GVL has demonstrated successful application in solid-phase peptide synthesis (SPPS), particularly in the anchoring of amino acids onto Wang resins, where it achieved high loading efficiencies with minimal racemization. These findings underscore GVL's suitability for peptide synthesis workflows and suggest its broader applicability in solution-phase amidation reactions as well. Importantly, GVL's ability


to preserve the stability of certain coupling reagents over extended durations represents a crucial advantage in multi-step synthesis settings.

While further research is needed to comprehensively establish GVL's compatibility with a range of coupling agents -including HATU, EDC and DIC - current findings position it as a strong candidate for replacing conventional, hazardous solvents in amidation chemistry.<sup>11</sup> To support this, some in-house examples were carried out wherein 2-[2-(*tert*-butoxycarbonylamino)ethoxy]acetic acid **8** was employed as the carboxylic acid component. In the first case, coupling with the aliphatic amine (*S,R,S*)-AHPC hydrochloride **901490** afforded the desired amide **9** in a 84% yield (**Figure 5**) whereas the same reaction afforded only 28% yield when conducted in DMF, further illustrating GVL's superior performance in practical amidation scenarios.




**Figure 5.** Synthesis of *tert*-butyl (2-(2-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)carbamate **9** from (*S,R,S*) AHPC hydrochloride **901490** and 2-(2-((*tert*-butoxycarbonyl)amino)ethoxy)acetic acid **8** in GVL **933856**.

In a subsequent reaction, the same acid **8** was coupled with the less nucleophilic aromatic amine C5-lenalidomide **911690**, yielding the corresponding amide in 82% (**Figure 6**). These experiments demonstrate that amidation - a transformation traditionally reliant on toxic solvents—can be effectively executed in GVL, achieving a significantly improved yield compared the literature result in DMF (57%)<sup>20</sup> while also better aligning with Green Chemistry principles.




**Figure 6.** Synthesis of C5 Lenalidomide-PEG1-NH-Boc **10** from C5 Lenalidomide **911690** and 2-(2-((*tert*-butoxycarbonyl)amino)ethoxy)acetic acid **8** in GVL **933856**.

Further, we explored the synthesis of benzyl ((*S*)-2-hydroxypropanoyl)-*L*-phenylalaninate **11** *via* amide bond formation between (*S*)-2-hydroxypropanoic acid **L1750** and benzyl *L*-phenylalaninate **78060** in GVL (**Figure 7**). Although the yield was lower (36%) compared to other amidation reactions performed in our laboratory, this transformation is noteworthy due to the structural complexity of the substrates. Specifically, the reaction occurs between a secondary amine and a sterically hindered, secondary carboxylic acid, making it a challenging system. In comparison, the same reaction conducted in DMF yielded 60%. Importantly, this example also highlights amide bond formation occurring selectively over esterification, emphasizing GVL's potential to support chemoselective transformations



**Figure 7.** Synthesis of benzyl ((*S*)-2-hydroxypropanoyl)-*L*-phenylalaninate **11** from (*S*)-2-hydroxypropanoic acid **L1750** and benzyl *L*-phenylalaninate **78060** in GVL **933856**.

In another study, we evaluated the coupling of an activated carboxylic acid, namely (+)-Biotin *N*-hydroxysuccinimide ester **H1759**, with *N*-Boc-1,4-butanediamine **15404** in GVL (**Figure 8**). The reaction proceeded efficiently to afford the corresponding amide in 80% yield. This transformation serves as a representative example of a chemical biology application, where such biotinylated products are widely used in Antibody–Drug Conjugates (ADCs) and drug discovery research. It is of note that although the 80% yield we report here is slightly lower than the literature report in DMF (85%)<sup>19</sup>, the reaction was run at room temperature opposed to 100 °C.




**Figure 8.** Synthesis of *tert*-butyl (4-(5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido)butyl)carbamate **12** from (+)-Biotin *N*-hydroxysuccinimide ester **H1759** and *N*-Boc-1,4-butanediamine **15404** in GVL **933856**.

### 3. Coupling Reactions

Cross-coupling reactions are essential synthetic methodologies for constructing a wide range of carbon–carbon and carbon–heteroatom bonds, playing a pivotal role in the synthesis of natural products, pharmaceuticals, agrochemicals and advanced materials.<sup>12</sup> Traditionally, these reactions are carried out in solvents such as NMP, DMF, 1,4-dioxane, toluene, MeCN, THF and dimethoxyethane, which offer strong solvation but pose significant health, environmental

and regulatory concerns. These challenges have intensified interest in greener solvent systems as part of more sustainable synthetic development.<sup>13</sup> Efforts to identify more sustainable alternatives include solvent screening studies and greener solvent selection guides. For example, Peng Lei<sup>14</sup> *et al.* utilized such a framework to carry out Suzuki–Miyaura couplings of amides in greener solvents like *tert*-butyl methyl ether (MTBE), Cyclopentyl Methyl Ether (CPME), Diethyl Carbonate (DEC), *p*-cymene, Dimethyl Carbonate (DMC) and anisole, replacing traditional dipolar aprotic and chlorinated solvents. In line with these efforts, we evaluated GVL as a more sustainable solvent for palladium-catalyzed cross-coupling reactions. Building on previous reports, including our earlier reference to the work by Strappaveccia<sup>4c</sup> *et al.*, which demonstrated the utility of GVL in Heck–Mizoroki couplings, we applied this greener solvent in our own synthetic experiments. To our delight, *tert*-butyl *N*-{[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl}carbamate **14** was synthesized via Heck coupling between *tert*-butyl (4-bromobenzyl)carbamate **13** and 4-methylthiazole **193925** in GVL, affording the desired product in an 82% yield after only 6 hours.



**Figure 9.** Synthesis of *tert*-butyl (4-(4-methylthiazol-5-yl)benzyl)carbamate **14** from *tert*-butyl (4-bromobenzyl)carbamate **13** and 4-methylthiazole **193925** in GVL **933856**.

### Reaction Summary

Several representative reactions were carried out in the lab to evaluate the performance of GVL as a greener solvent compared to traditionally used hazardous solvents. The results, summarized in **Table 3**, demonstrate GVL's broad applicability across multiple reaction classes.

**Table 3.** Yield of reactions in GVL and their comparison with conventional solvents

Reaction Type	Reaction Reference	Reported in Literature				Experimental Findings in GVL		
		Solvent	Time	Temperature	Yield (%)	Time	Temperature	Yield (%)
$S_NAr$	Figure 2	DMF <sup>15</sup>	4 h	90 °C	82	5 h	90 °C	87
		NMP <sup>16</sup>	5 h	90 °C	79			
<i>N</i> -Alkylation	Figure 3	DMF <sup>17</sup>	3 h	Ambient	76	4 h	Ambient	98
	Figure 4	DMF <sup>18</sup>	18 h	80 °C	82	4 h	90 °C	83
	Figure 5	DMF <sup>19</sup>	15 h	Ambient	28	18 h	Ambient	84
	Figure 6	DMF <sup>20</sup>	18 h	Ambient	57	18 h	Ambient	82
Amidation	Figure 7	DMF <sup>20</sup>	8 h	Ambient	60	16 h	Ambient	36
	Figure 8	DMF <sup>20</sup>	16 h	100 °C	85	16 h	Ambient	80
Heck coupling	Figure 9	DMF <sup>21</sup>	18 h	140 °C	94	6 h	110 °C	82

Notably, in a  $S_NAr$  reaction, where conventional protocols rely on NMP or DMF - GVL enabled an equivalent or superior yield, confirming its capability to replace dipolar aprotic solvents in demanding transformations. Similarly, in amide bond formation, GVL performed exceptionally well under the same time and temperature conditions, delivering improved yields over standard solvents. However, limitations were observed in  $S_NAr$  reactions involving azide substitution. When attempting to displace chloride with azide under basic conditions, no desired product was formed, likely due to nucleophilic attack of the azide anion on the lactone ring of GVL, leading to solvent decomposition. Despite this limitation, the overall performance of GVL across most reaction types was highly encouraging and supports its adoption as a safer, more sustainable solvent in synthetic workflows.

While GVL offers substantial benefits, challenges such as cost-effective large-scale production and global supply integration still hinder its widespread use. However, innovations in reactive distillation and hybrid catalytic pathways are making GVL increasingly viable at commercial scale. As regulatory pressure mounts on toxic solvents, GVL is poised to play a critical role in advancing greener industrial practices.

## Conclusion

This application note establishes GVL as a versatile and high-performing bio-based solvent capable of replacing traditional dipolar aprotic solvents such as

DMF, NMP, and DMAc across a wide range of synthetic transformations. Through both literature review and in-house experimentation, GVL demonstrated excellent performance in key reaction classes including  $S_NAr$ , *N*-alkylation, amidation, and Pd-catalyzed coupling.

GVL consistently delivered comparable or superior yields under similar conditions, as summarized in **Table 3**, reinforcing its synthetic efficacy. Notably, it enabled several complex and high-value reactions, including the formation of privileged medicinal scaffolds and peptide-like amides - highlighting its relevance in drug discovery, chemical biology, and materials science.

Beyond reactivity, GVL offers significant operational advantages: low toxicity, high thermal stability, ease of handling, low volatility, and minimal residual contamination. These features make it suitable for both bench-scale and process-scale applications. While limitations were observed in lactone ring degradation under harsh conditions - such cases are exceptions rather than the norm.

As regulatory pressure intensifies on toxic solvents and innovations in biomass valorization improve GVL's commercial viability, this solvent is well-positioned to become a mainstream component of greener synthetic chemistry. Its alignment with Green Chemistry principles, combined with robust performance across diverse reaction types, supports its broader adoption in both academic and industrial settings.

## Featured Products

Description	Cat. No.
<b>Solvent</b>	
$\gamma$ -Valerolactone, BioRenewable, anhydrous, DMF and NMP substitute, $\geq 99\%$	<b>933856</b>

## Related Products

Description	Cat. No.
<b>Key Raw Materials and Reagents</b>	
4-methylthiazole, 99%	<b>193925</b>
Potassium acetate, ReagentPlus®, $\geq 99.0\%$	<b>P1147</b>
<i>N,N</i> -Diisopropylethylamine, ReagentPlus®, $\geq 99\%$	<b>D125806</b>
Benzyl bromoacetate, 96%	<b>245631</b>
Potassium carbonate, anhydrous, free-flowing, Redi-Dri™, ACS reagent, $\geq 99\%$	<b>791776</b>
<i>tert</i> -butyl (4-aminobutyl)carbamate <i>N</i> -Boc-1,4-butanediamine, $\geq 97.0\%$ (GC/NT)	<b>15404</b>
2,5-dioxopyrrolidin-1-yl 5-((3a <i>S</i> ,4 <i>S</i> ,6a <i>R</i> )-2-oxohexahydro-1 <i>H</i> -thieno[3,4- <i>d</i> ]imidazol-4-yl) pentanoate, $\geq 98\%$ (HPLC), powder	<b>H1759</b>
Sodium acetate, anhydrous, ReagentPlus®, $\geq 99.0\%$	<b>S8750</b>
L-Phenylalanine benzyl ester hydrochloride, $\geq 99.0\%$ (AT)	<b>78060</b>
L-(+)-Lactic acid, $\geq 98\%$	<b>L1750</b>
C5 Lenalidomide, $\geq 95\%$	<b>911690</b>

Description	Cat. No.
<b>Key Raw Materials and Reagents</b>	
(S,R,S) AHPC hydrochloride, ≥97%	<b>901490</b>
Sodium bicarbonate, anhydrous, free-flowing, Redi-Dri™, ACS reagent, ≥99.7%	<b>792519</b>
1-Boc-piperazine, 97%	<b>343536</b>
HATU, 97%, for peptide synthesis	<b>445460</b>
<b>Catalysts</b>	
Palladium(II) acetate, reagent grade, 98%	<b>205869</b>
<b>Solvents Other</b>	
Acetic acid, glacial, ACS reagent, ≥99.7%	<b>695092</b>
Ethyl alcohol, Pure, ≥99.5%, ACS reagent	<b>459844</b>

See more information on our offering for greener solvents on [SigmaAldrich.com/biorenewable-solvents](https://www.sigmaaldrich.com/biorenewable-solvents)

## References

- (a) Reducing Environmental Impact Of Organic Synthesis. <https://cen.acs.org/articles/91/i15/Reducing-Environmental-Impact-Organic-Synthesis.html>. (b) Candidate List of substances of very high concern for Authorisation. <https://echa.europa.eu/candidate-list-table>. (c) Alder, C. M.; Hayler, J. D.; Henderson R. K.; Redman, A. M.; Shukla, L.; Shuster L. E.; Sneddon, H. F. Updating and further expanding GSK's solvent sustainability guide. *Greener Chem.*, **2016**, *18*, 3879–3890. <https://doi.org/10.1039/c6gc00611f>. (d) Prat, D.; Wells, A.; Hayler, J.; Sneddon, H.; McElroy, C. R.; Abou-Shehada, S.; Dunn, P. J. CHEM21 selection guide of classical- and less classical-solvents. *Greener Chem.*, **2016**, *18*, 288–296. <https://doi.org/10.1039/c5gc01008j>. (e) Nomiya, T.; Tsukahara, T.; Hasegawa, K.; Health risks of N,N-dimethylacetamide (DMAC) in humans. *J. Occup. Health.*, **2025**, *67*(1). <https://doi.org/10.1093/jocchu/uaif010>. (f) Bryan, M. C.; Dunn, P. J.; Entwistle, D.; Gallou, F.; Koenig, S. G.; Hayler, J. D.; Hickey, M. R.; Hughes, S.; Kopach, M. E.; Moine, G. Key Greener Chemistry research areas from a pharmaceutical manufacturers' perspective revisited. *Greener Chem.*, **2018**, *20*, 5082–5103. <https://doi.org/10.1039/C8GC01276H>. (g) NMP Substance Infocard; ECHA, **2020**. <https://echa.europa.eu/substance-information/-/substanceinfo/100.011.662>. (h) DMF Substance Infocard; ECHA, **2020**. <https://echa.europa.eu/substance-information/-/substanceinfo/100.000.617>. (i) DMAC Substance Infocard; ECHA, **2020**. <https://echa.europa.eu/substance-information/-/substanceinfo/100.004.389>. (j) Anastas, P. T.; Warner, J. C. **1998**. *Green Chemistry: Theory and Practice*. Oxford University Press. <https://doi.org/10.1093/oso/9780198506980.001.0001>. (k) Rosas, B. H.; Muñoz, M. C.; Ramírez, J.J.Q.; Barrera, C. R. C.; Zarazúa, G. C.; Hernández, J. G. S.; Ramírez, E. S. Intensified alternative for more sustainable gamma-valerolactone production from levulinic acid. *Chemical Engineering Research and Design*, **2025**, *217*, 38–48. <https://doi.org/10.1016/j.chemd.2025.03.023>. (l) Prati, L.; Jouve, A.; Villa, A. (2017). Production and Upgrading of  $\gamma$ -Valerolactone with Bifunctional Catalytic Processes. In: Fang, Z., Smith Jr., R., Li, H. (eds) *Production of Biofuels and Chemicals with Bifunctional Catalysts*. *Biofuels and Biorefineries*, vol 8. Springer, Singapore. [https://doi.org/10.1007/978-981-10-5137-1\\_7](https://doi.org/10.1007/978-981-10-5137-1_7)
- (a) Fodor, D.; Kégl, T.; Tukacs, J. M.; Horváth, A. K.; Mika, L. T. Homogeneous Pd-Catalyzed Heck Coupling in  $\gamma$ -Valerolactone as a Greener Reaction Medium: A Catalytic, Kinetic, and Computational Study. *ACS Sustainable Chem. Eng.*, **2020**, *8* (26), 9926–9936. <https://doi.org/10.1021/acssuschemeng.0c03523>. (b) Orha, L.; Tukacs, J. M.; Kollar, L.; Mika, L. T. Palladium-catalyzed Sonogashira coupling reactions in  $\gamma$ -valerolactone-based ionic liquids. *Beilstein J. Org. Chem.*, **2019**, *15*, 2907–2913. <https://doi.org/10.3762/bjoc.15.284>. (c) Ferrazzano, L.; Martelli, G.; Fantoni, T.; Daka, A.; Corbisiero, D.; Viola, A.; Ricci, A.; Cabri, W.; Tolomelli, A. Fast Heck-Cassar-Sonogashira (HCS) Reactions in Green Solvents. *Org. Lett.*, **2020**, *22*(10), 3969–3973. <https://pubs.acs.org/doi/10.1021/acs.orglett.0c01269>. (d) Jordan, A.; Hall, C. G. J.; Thorp, L. R.; Sneddon, H. F.; Replacement of Less-Preferred Dipolar Aprotic and Ethereal Solvents in Synthetic Organic Chemistry with More Sustainable Alternatives. *Chem. Rev.*, **2022**, *122* (6), 6749–6794. <https://pubs.acs.org/doi/10.1021/acs.chemrev.1c00672>. (e) Jad, Y. E.; Govender, T.; Kruger, H. G.; El-Faham, A.; de la Torre, B. G.; Albericio, F. Green Solid-Phase Peptide Synthesis (GSPPS) 3. Green Solvents for Fmoc Removal in Peptide Chemistry. *Org. Process Res. Dev.*, **2017**, *21* (3), 365–369. <https://pubs.acs.org/doi/10.1021/acs.oprd.6b00439>
- Horváth, I. T.; Mehdi, H.; Fábos, V.; Bodaab, L.; Mika L.T.  $\gamma$ -Valerolactone—a sustainable liquid for energy and carbon-based chemicals. *Green Chem.*, **2008**, *10*, 238–242. <https://doi.org/10.1039/B712863K>
- (a) Fodor, D.; Kégl, T.; Tukacs, J. M.; Horváth, A. K.; Mika, L. T. Homogeneous Pd-Catalyzed Heck Coupling in  $\gamma$ -Valerolactone as a Greener Reaction Medium: A Catalytic, Kinetic, and Computational Study. *ACS More sustainable Chem. Eng.*, **2020**, *8*, 9926–9936. <https://dx.doi.org/10.1021/acssuschemeng.0c03523>. (b) Kerkel, F.; Markiewicz, M.; Stolte, S.; Müllerca, E.; Kunz, W. The greener platform molecule gamma-valerolactone – ecotoxicity, biodegradability, solvent properties, and potential applications. *Greener Chem.*, **2021**, *23*, 6279–6293. <https://doi.org/10.1039/D0GC04353B>. (c) Strappaveccia, G.; Ermal Ismalaj, Chiara Petrucci, Daniela Lanari, Assunta Marrochi, Martin Drees, Antonio Facchetti\*, and Luigi Vaccaro. A biomass-derived safe medium to replace toxic dipolar solvents and access cleaner Heck coupling reactions. *Greener Chem.*, **2015**, *17*, 365–372. <https://doi.org/10.1039/c4gc01677g>
- (a) Worsley, C.; Raptis, D.; Meroni, S.; Doolin, A.; Garcia-Rodriguez, R.; Davies, M.; Watsony, T. Valerolactone: A Nontoxic Greener Solvent for Highly Stable Printed Mesoporous Perovskite Solar Cells. *Energy Technol.*, **2021**, *9*, 2100312. <https://doi.org/10.1002/ente.202100312>. (b) Miao, Y.; Ren, M.; Chen, Y.; Wang, H.; Chen, H.; Liu, X.; Wang, T.; Zhao, Y. Greener solvent enabled scalable processing of perovskite solar cells with high efficiency. *Nat. Sustain.*, **2023**, *6*, 1465–1473. <https://doi.org/10.1038/s41893-023-01196-4>
- Winters, J.; Dehaen, W.; Binnemans, K.  $\gamma$ -Valerolactone-based organic electrolyte solutions: a benign approach to polyaramid. *Greener Chem.*, **2020**, *22*, 6127–6136. <https://doi.org/10.1039/D0GC02324H>
- (a) Guesmi, N. E.; Berionni, G.; Asghar, B. A. Electronic and solvent effects on kinetics of SNAR substitution reactions of substituted anilines with 2,6-bis-(trifluoromethanesulfonyl)-4-nitroanisole in MeOH–Me2SO mixtures of varying composition: one reaction with two mechanistic pathways. *Monatsh Chem.*, **2013**, *144*, 1537–1545. <https://doi.org/10.1007/s00706-013-1030-7>. (b) Gazitúa, M.; Tapia, R. A.; Contreras, R.; Campodónico, P. R. Effect of the nature of the nucleophile and solvent on an SNAR reaction. *New J. Chem.*, **2018**, *42*, 260–264. <https://doi.org/10.1039/C7NJ03212A>
- (a) Zhu, X.; Giordano, T.; Yu, Q.-S.; Holloway, H. W.; Perry, T. A.; Lahiri, D. K.; Brossi, A.; Greig, N. H. Thiothalidomides: Novel Isosteric Analogues of Thalidomide with Enhanced TNF- $\alpha$  Inhibitory Activity. *J. Med. Chem.*, **2003**, *46* (24), 5222–5229. <https://doi.org/10.1021/jm030152f>. (b) Bricelj, A.; Steinebach, C.; Kuchta, R.; Gütschow, M.; Sosic, I. E3 Ligase Ligands in Successful PROTACs: An Overview

- of Syntheses and Linker Attachment Points. *Front. Chem.*, **2021**, 9, Art. 707317. <https://doi.org/10.3389/fchem.2021.707317> (c) Xiao, Z.; Schaefer, K.; Firestine, S.; Li, P.-K. Solid-Phase Synthesis of Thalidomide and Its Analogues. *J. Comb. Chem.* **2002**, 4, 2, 149–153 and the references cited therein. <https://doi.org/10.1021/cc010038n>
- Procopio, D.; Siciliano, C.; Trombino, S.; Dumitrescu, D. E.; Suciub, F.; Gioia, M. L. D.; Green solvents for the formation of amide linkages. *Org. Biomol. Chem.*, **2022**, 20, 1137–1149. <https://doi.org/10.1039/D1OB01814K>
  - Martin V, Egelund PHG, Johansson H, Thordal Le Quement S, Wojcik F, Sejer Pedersen D. Greening the synthesis of peptide therapeutics: an industrial perspective. *RSC Adv.*, **2020**, 10(69), 42457–42492. <https://doi.org/10.1039/d0ra07204d>
  - MacMillan, D. S.; Murray, J.; Sneddon, H. F.; Jamieson, C.; Watson, A. J. B. Evaluation of alternative solvents in common amide coupling reactions: replacement of dichloromethane and *N,N*-dimethylformamide. *Greener Chem.*, **2013**, 15, 596–600. <https://doi.org/10.1039/C7NJ03212A>
  - Nicolaou, K.C.; Bulge, P.G.; Sarlah, D. Palladium-catalyzed cross-coupling reactions in total synthesis. *Angew. Chem. Int. Ed.*, **2005**, 44, 4442–4489. <https://doi.org/10.1002/anie.200500368>
  - Sherwood, J.; Clark, J. H.; Fairlamb, I. J. S.; Slattery, J. M. Solvent effects in palladium catalysed cross-coupling reactions. *Greener Chem.*, **2019**, 21, 2164–2213. <https://doi.org/10.1039/C9GC00617F>
  - Lei, P.; Mu, Y.; Wang, Y.; Wang, Y.; Ma, Z.; Feng, J.; Liu, X.; Szostak, Michal. Greener Solvent Selection for Suzuki–Miyaura Coupling of Amides. *ACS More sustainable Chem. Eng.*, **2021**, 9(1), 552–559. <https://doi.org/10.1021/acssuschemeng.0c08044>
  - Preparation of 2-(2,6-dioxo-3-piperidyl)isoindoline-1,3-dione 4-[2-(2-cyclopentylidenehydrazino)thiazol-4-yl]benzoxonitrile derivatives for prevention/treatment of tumor. Assignee: Shenzhen Hospital of Southern Medical University. China, CN116514798 A **2023-08-01**.
  - Zhang, F.; Yu, Q.; Wu, C.; Sun, S.; Wang, Y.; Wang, R.; Chen, Z.; Zhang, H.; Xiong, X.; Awadasseid, A. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction. *Bioorg. Med. Chem.*, **2024**, 111, 117867. <https://doi.org/10.1016/j.bmc.2024.117867>
  - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof Assignees: Nurix Therapeutics, Inc.; Gilead Sciences, Inc. World Intellectual Property Organization, WO2021226262 A1 **2021-11-11**. <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021226262>
  - Compounds modulating protein recruitment and/or degradation Assignee: Orionis Biosciences, Inc. World Intellectual Property Organization, WO2021126973 A1 **2021-06-24** <https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021126973>
  - Aza-androstene-carboxamide compound for inhibiting nuclear receptor or inducing degradation of nuclear receptor. Assignee: Daewoong Therapeutics Inc. Korea, Republic of, KR2023140396 A **2023-10-06**.
  - In house experimentations.
  - Cooper, M. S.; Norley, M. C.; Armitage, S.; Brown, J. O. C.; Anthony, K. E.; Goggins, S.; Hopewell, J. P.; Karadogan, B.; Knights, K. A.; Nash, T. J.; Oakes, C. S.; O'Neill, W. J.; Pridmore, S. J.; Maple, H. J.; Marsh, G. P. Efficient, multi-hundred-gram scale access to E3 ubiquitin ligase ligands for degrader development. *Org. Biomol. Chem.*, **2023**, 21, 8344–8352. <https://doi.org/10.1039/D3OB00983A>

## Appendix

### General Experimental Information

All commercially available reagents and solvents were used as received without further purification unless otherwise stated. Reactions were carried out under an inert atmosphere of nitrogen or argon in flame-dried or oven-dried glassware. Solvents used for reactions and chromatography were dried using standard procedures where required. Reaction progress was monitored by thin-layer chromatography on pre-coated silica gel

plates (TLC aluminum sheets, Silica gel 60 F<sub>254</sub>), and compounds were visualized using UV light or appropriate staining agents. Flash column chromatography was performed using silica gel (100–200 mesh). Organic solvents were removed under reduced pressure using a rotary evaporator, and products were dried under high vacuum. Purity and identity of compounds were confirmed by spectroscopic and analytical techniques. Nuclear magnetic resonance (NMR) spectra were recorded on a 400 MHz Bruker spectrometer. Chemical shifts ( $\delta$ ) are reported in parts per million (ppm) relative to the residual solvent peak. Coupling constants (*J*) are reported in hertz (Hz). Melting points were determined using a Buchi apparatus and are uncorrected. Specific synthetic procedures and characterization data for each compound are detailed below.

### Experimental Procedures

#### Synthesis of *tert*-butyl 4-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-4-yl)piperazine-1-carboxylate **2** (Figure 2)

In a 100 mL round-bottom flask equipped with a nitrogen inlet and a condenser, 2-(2,6-Dioxo-3-piperidyl)-4-fluoro-1*H*-isoindole-1,3(2*H*)-dione **1** (1.00 g, 3.62 mmol, 1.0 equiv) and *N*-Boc-piperazine **343536** (0.809 g, 4.34 mmol, 1.20 equiv.) were added to  $\gamma$ -valerolactone **933856** (15 mL). The resulting suspension was stirred for 10 minutes, after which *N,N*-diisopropylethylamine **D125806** (1.40 g, 3.0 equiv., 10.9 mmol) was added dropwise. The reaction mixture was then heated to 90 °C and stirred for 5 hours. During the reaction, the suspension gradually turned from grayish to yellow. After completion, the mixture was cooled to room temperature, resulting in precipitation of the product. The solid was collected by filtration using a Büchner funnel, washed with water (2 X 50 mL), and dried to yield the target compound, 1,1-dimethylethyl-4-[2-(2,6-dioxo-3-piperidyl)-2,3-dihydro-1,3-dioxo-1*H*-isoindol-4-yl]-1-piperazinecarboxylate **2** (1.40 g, 87%), as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 400 MHz):  $\delta$  8.00 (s, 1H), 7.53 (t, *J* = 8.0 Hz, 1H), 7.36 (d, *J* = 8.0 Hz, 1H), 7.11 (d, *J* = 8.0 Hz, 1H), 4.87 (dd, *J* = 8.0 Hz, 1H), 3.58 (t, *J* = 8.0 Hz, 4H), 3.21 (t, *J* = 8.0 Hz, 4H), 2.81–2.66 (m, 3H), 2.04 (m, 1H), 1.43 (s, 9H) ppm.

#### Synthesis of *tert*-butyl 7-(2-(benzyloxy)-2-oxoethyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate **4** (Figure 3)

A 100 mL three-neck round-bottom flask was equipped with a nitrogen inlet and charged with *tert*-butyl 2,7-diazaspiro[3.5]nonane-2-carboxylate **3** (1.0 g, 4.42 mmol, 1.0 equiv.) in  $\gamma$ -valerolactone **933856** (20 mL). To this solution, potassium carbonate **791776** (1.83 g, 13.26 mmol, 3.0 equiv.) was added and the mixture was stirred for 10 minutes. Benzyl 2-bromoacetate **245631** (1.21 g, 1.2 equiv, 5.30 mmol) was then added, and the reaction mixture was stirred at room temperature for 4 h. After completion, the reaction was quenched by pouring into ice water and extracted with ethyl acetate (3 X 100 mL). The combined organic layers were washed with saturated NaHCO<sub>3</sub> solution (30 mL) and brine

(50 mL), then dried over anhydrous sodium sulfate. The solution was filtered and concentrated under reduced pressure to afford the crude product. Purification was carried out by column chromatography on silica gel (100–200 mesh), eluting with 15–20% ethyl acetate in hexane. The desired product, 7-benzyl 2-(*tert*-butyl) 2,7-diazaspiro[3.5]nonane-2,7-dicarboxylate **4** (1.62 g, 98%), was obtained as a white solid. TLC:  $R_f$  0.53 in 30% ethyl acetate in *n*-hexane. visualized by heating with ninhydrin stain.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  7.32–7.25 (m, 5H), 5.09 (s, 2H), 3.53 (s, 4H), 3.20 (s, 2H), 2.45 (s, 4H), 1.73 (t,  $J = 6.0$  Hz, 4H), 1.37 (s, 9H) ppm.

### Synthesis of 3-(5-nitro-1-oxoisindolin-2-yl)piperidine-2,6-dione **7** (Figure 4)

To a stirred solution of 2-(bromomethyl)-4-nitrobenzoate **5** (2.74 g, 1.0 mmol, 1.0 equiv) and 3-aminoglutarimide hydrochloride **6** (1.98 g, 1.20 mmol, 1.2 equiv) in  $\gamma$ -valerolactone **933856** (15 mL), *N,N*-diisopropylethylamine **D125806** (0.52 g, 0.7 mL, 4.0 mmol, 4.0 equiv) was added. The reaction mixture was stirred at 90 °C for 4 h. After completion, the mixture was cooled to room temperature and diluted with water (30 mL). The resulting precipitate was filtered, washed with water, and dried to afford 3-(5-nitro-1-oxoisindolin-2-yl)piperidine-2,6-dione **7** (2.40 g, 83%) as a bluish-gray solid. TLC:  $R_f$  0.60 in 10% methanol in dichloromethane, visualized under UV light (fluorescent and UV-active).  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ , 400 MHz):  $\delta$  11.06 (brs, 1H), 8.54 (s, 1H), 8.36 (dd,  $J = 2.1, 8.4$  Hz, 1H), 7.98 (d,  $J = 8.3$  Hz, 1H), 5.16 (dd,  $J = 5.1, 13.3$  Hz, 1H), 4.44 – 4.66 (m, 2H), 2.85 – 2.98 (m, 1H), 2.57 – 2.69 (m, 1H), 2.36 – 2.47 (m, 1H), 2.01 – 2.10 (m, 1H) ppm.

### Synthesis of *tert*-butyl (2-(2-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)carbamate **9** (Figure 5)

In a 50 mL three-neck round-bottom flask equipped with a nitrogen inlet, 2-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]ethoxy]acetic acid **8** (0.26 g, 1.19 mmol, 1.2 equiv) and HATU **445460** (0.566 g, 1.49 mmol, 1.5 equiv) were dissolved in  $\gamma$ -valerolactone **933856** (10 mL). The solution was stirred at room temperature for 10 minutes, then cooled to 0 °C using an ice-water bath. To this, (*S,R,S*)-AHPC hydrochloride **901490** (0.50 g, 0.99 mmol, 1.0 equiv) was added, followed by *N,N*-diisopropylethylamine **D125806** (0.52 mL, 2.97 mmol, 3.0 equiv). The reaction mixture was stirred at room temperature for 18 h. Upon completion, it was poured into ice-cold water and extracted with ethyl acetate (100 mL). The organic layer was washed with saturated  $\text{NaHCO}_3$  solution (50 mL) and brine (50 mL), then dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield the crude product. The crude residue was purified by column chromatography on silica gel (100–200 mesh) using 2–3% methanol in dichloromethane as eluent to afford the product as a colorless sticky solid *tert*-butyl (2-(2-(((*S*)-1-((2*S*,4*R*)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)carbamate **9** (0.53 g, 84%). TLC:

$R_f$  0.7 in 5% methanol in dichloromethane.  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ , 400 MHz):  $\delta$  9.05 (s, 1H), 8.65 (t,  $J = 8.0$  Hz, 1H), 7.52 (d,  $J = 8.0$  Hz, 1H), 7.50–7.46 (d,  $J = 8.0$  Hz, 4H), 6.95 (t,  $J = 8.0$  Hz, 1H), 5.22 (brs, 1H), 4.61 (d,  $J = 8.0$  Hz, 1H), 4.45–4.35 (m, 3H), 4.32–4.28 (m, 1H), 4.01 (s, 2H), 3.72–3.65 (m, 2H), 3.51 (t,  $J = 8.0$  Hz, 2H), 3.19–3.17 (t,  $J = 8.0$  Hz, 2H), 2.51 (s, 3H), 2.11 (m, 1H), 1.97 (m, 1H), 1.43 (s, 9H), 1.01 (s, 9H) ppm.

### Synthesis of C5 Lenalidomide-PEG1-NH-Boc [*tert*-butyl (2-(2-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisindolin-5-yl)amino)-2-oxoethoxy)ethyl)carbamate] **10** (Figure 6)

In a 50 mL, three neck RB flask equipped with nitrogen inlet, 2-[2-[[[(1,1-Dimethylethoxy)carbonyl]amino]ethoxy]acetic acid **8** (0.26 g, 1.2 mol, 1.20 equiv) and HATU **445460** (0.57 g, 1.49 mol, 1.5 equiv) were added in 10 mL  $\gamma$ -Valerolactone **933856**. The solution was stirred for 10 minutes at room temperature to dissolve and the cooled to 0 °C using ice cold water and C5 Lenalidomide **911690** (0.50 g, 0.99 moles, 1.0 equiv) was added, followed by addition of *N,N*-diisopropylethylamine **D125806** (0.5 mL, 2.90 moles, 3.0 equiv). The reaction mixture was stirred at room temperature for 18h, after completion (checked by TLC;  $R_f$  0.58 in 7% methanol in dichloromethane) poured into ice cold water. Reaction mixture was precipitated out and the resulting precipitate was collected by filtration through buchner funnel. The residual solid was washed with water (50 mL X 2) and dried to afford the product as gray solid C5 Lenalidomide-PEG1-NH-Boc **10** (0.73 g, 82%).  $^1\text{H}$  NMR ( $\text{DMSO-d}_6$ , 400 MHz):  $\delta$  10.99 (s, 1H), 9.95 (s, 1H), 8.03 (s, 1H), 7.73 (m 2H), 6.99 (s, 1H), 5.10 (dd,  $J = 4.0$  Hz, 1H), 4.43–4.29 (dd,  $J = 4.0$  Hz, 2H), 4.11 (s, 2H), 3.52 (t,  $J = 4.0$  Hz, 2H), 3.18 (t,  $J = 6.0$  Hz, 2H), 2.95 (m, 1H), 2.51 (m, 1H), 2.37 (m, 1H), 2.01 (m, 1H), 1.43 (s, 9H) ppm.

### Synthesis of benzyl ((*S*)-2-hydroxypropanoyl)-*L*-phenylalaninate **11** (Figure 7)

In a 100 mL three-neck round-bottom flask equipped with a nitrogen inlet, (*S*)-2-hydroxypropanoic acid **L1750** (1.0 g, 11.10 mmol, 1.0 equiv) was dissolved in  $\gamma$ -valerolactone **933856** (20 mL) and cooled to 0 °C. To this solution, HATU **445460** (5.06 g, 13.32 mmol, 1.2 equiv) was added, and the mixture was stirred for 10 minutes at the same temperature. Subsequently, benzyl *L*-phenylalaninate **78060** (3.24 g, 11.10 mmol, 1.0 equiv) was added, followed by *N,N*-diisopropylethylamine **D125806** (9.82 mL, 55.50 mmol, 5.0 equiv) dropwise *via* an addition funnel over 10–15 minutes at 0 °C. The light brown reaction mixture was then allowed to stir at room temperature for 16 hours. After completion, the reaction was poured into ice-cold water (20 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic layers were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to yield a crude amorphous solid. The crude residue was purified by column chromatography on silica gel (100–200 mesh) using 30–40% ethyl acetate in hexane as eluent. Pure fractions were combined and concentrated to afford the product as a white solid benzyl ((*S*)-2-

hydroxypropanoyl)-L-phenylalaninate **11** (1.32 g, 36%). TLC:  $R_f$  0.4 in 50% EtOAc in hexane.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  7.35-7.30 (m, 3H), 7.29-7.24 (m, 2H), 7.16-7.08 (m, 3H), 6.96-6.93 (m, 2H), 6.87-6.85 (m, 1H), 5.09 (q, 2H,  $J = 12.0$  Hz), 4.87-4.82 (m, 1H), 4.14-4.09 (m, 1H), 3.13-3.00 (m, 2H), 1.27 (d, 3H,  $J = 4$  Hz).

#### Synthesis of *tert*-butyl (4-(5-((3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido)butyl)carbamate **12** (Figure 8)

A 3-neck, 50 mL round-bottom flask was equipped with a nitrogen bubbler, and a solution of (+)-biotin *N*-hydroxysuccinimide ester **H1759** (1.0 g, 2.93 mmol, 1.0 equiv) in  $\gamma$ -valerolactone **933856** (30 mL) was added. The mixture was stirred until a clear solution was obtained. Then, *N*-Boc-1,4-butanediamine **15404** (0.61 g, 3.22 mmol, 1.1 equiv) was added, and the reaction mixture was stirred at room temperature for 18 h. After completion, diethyl ether (100 mL) was added, and the mixture was stirred for an additional 30 minutes. The resulting precipitate was filtered through a Büchner funnel and washed with ethyl acetate (25 mL). The residue was dried for 4 h to afford *tert*-butyl (4-(5-((3*a*S,4*S*,6*a*R)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido)butyl)carbamate **12** (0.97 g, 80%) as a white solid. TLC:  $R_f$  0.38 in 10% methanol in dichloromethane; Visualisation by PMA stain.  $^1\text{H}$  NMR ( $\text{DMSO-}d_6$ , 400 MHz):  $\delta$  7.76-7.74 (t,  $J = 8.0$  Hz, 1H), 6.80-6.78 (t,  $J = 8.0$  Hz, 1H), 6.37 (s, 1H), 6.32 (s, 1H), 4.32 (t,  $J = 8.0$  Hz, 1H), 4.12 (t,  $J = 8.0$  Hz, 1H),

3.11-2.82 (m, 6H), 2.56 (d,  $J = 12$  Hz, 1H), 2.06 (t,  $J = 8.0$  Hz, 2H), 1.62-1.27 (m, 19H) ppm.

#### Synthesis of *tert*-butyl (4-(4-methylthiazol-5-yl)benzyl)carbamate **14** (Figure 9)

To a stirred solution of *tert*-butyl(4-bromobenzyl)carbamate **13** (2.0 g, 6.99 mmol, 1.0 equiv) in  $\gamma$ -valerolactone **933856** (20 mL) at ambient temperature, 4-methylthiazole **193925**, (1.39 g, 13.98 mmol, 2.0 equiv) and potassium acetate **P1147** (1.37 g, 13.98 mmol, 2.0 equiv) were added. Nitrogen was bubbled through the reaction mixture for 10 minutes, after which palladium(II) acetate **205869** (0.157 g, 0.699 mmol, 0.1 equiv) was added. Then the reaction mixture was heated to 90 °C and stirred for 6 h. Upon completion, the reaction was cooled to room temperature, poured into water (100 mL), and extracted with ethyl acetate (250 mL). The organic layer was washed with water (100 mL), dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by column chromatography on silica gel (100–200 mesh) using hexane-ethyl acetate as the eluent to yield *tert*-butyl (4-(4-methylthiazol-5-yl)benzyl)carbamate **14** as a white powder (1.74 g, 82%). TLC:  $R_f$  0.80 in 30% ethyl acetate in hexane. Visualisation through 254 nm UV light in chamber.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 400 MHz):  $\delta$  8.62 (s, 1H), 7.33 (d,  $J = 8.0$  Hz, 2H), 7.29 (d,  $J = 8.0$  Hz, 2H), 4.86 (brs, 1H), 4.28 (d,  $J = 8.0$  Hz, 2H), 2.46 (s, 3H), 1.40 (s, 9H) ppm.

## To place an order or receive technical assistance

In Europe, please call Customer Service:

France: 0825 045 645 Spain: 901 516 645 Option 1  
Germany: 069 86798021 Switzerland: 0848 645 645  
Italy: 848 845 645 United Kingdom: 0870 900 4645

For other countries across Europe, please call: +44 (0) 115 943 0840

Or visit: [SigmaAldrich.com/offices](https://www.sigmaaldrich.com/offices)

For Technical Service visit: [SigmaAldrich.com/techservice](https://www.sigmaaldrich.com/techservice)

[SigmaAldrich.com](https://www.sigmaaldrich.com)

We have built a unique collection of life science brands with unrivalled experience in supporting your scientific advancements.

Millipore® Sigma-Aldrich® Supelco® Milli-Q® SAFC® BioReliance®

Merck KGaA  
Frankfurter Strasse 250  
64293 Darmstadt, Germany

